Your browser is no longer supported. Please, upgrade your browser.
Settings
CHRS [NASD]
Coherus BioSciences, Inc.
Index- P/E8.05 EPS (ttm)2.02 Insider Own0.40% Shs Outstand71.65M Perf Week-5.96%
Market Cap1.14B Forward P/E14.98 EPS next Y1.08 Insider Trans-49.49% Shs Float64.13M Perf Month-24.08%
Income161.80M PEG3.66 EPS next Q0.23 Inst Own- Short Float20.40% Perf Quarter-13.16%
Sales489.30M P/S2.33 EPS this Y138.10% Inst Trans4.35% Short Ratio10.91 Perf Half Y-14.14%
Book/sh3.57 P/B4.55 EPS next Y-36.98% ROA26.60% Target Price29.90 Perf Year-15.37%
Cash/sh7.18 P/C2.26 EPS next 5Y2.20% ROE88.40% 52W Range10.86 - 22.22 Perf YTD-6.56%
Dividend- P/FCF8.63 EPS past 5Y16.20% ROI37.00% 52W High-26.90% Beta1.29
Dividend %- Quick Ratio5.20 Sales past 5Y62.80% Gross Margin93.10% 52W Low49.52% ATR1.17
Employees306 Current Ratio5.40 Sales Q/Q1.70% Oper. Margin37.80% RSI (14)41.71 Volatility7.06% 7.06%
OptionableYes Debt/Eq1.58 EPS Q/Q-44.50% Profit Margin33.10% Rel Volume1.18 Prev Close15.25
ShortableYes LT Debt/Eq1.58 EarningsFeb 24 AMC Payout0.00% Avg Volume1.20M Price16.24
Recom1.90 SMA20-8.48% SMA50-8.79% SMA200-9.96% Volume1,412,074 Change6.49%
Jul-16-20Initiated BofA Securities Neutral $20
Apr-17-20Initiated SunTrust Buy $26
Aug-13-19Initiated Mizuho Buy
Aug-02-19Reiterated Maxim Group Buy $25 → $27
Aug-02-19Reiterated H.C. Wainwright Buy $28 → $29
Jun-11-19Initiated Barclays Overweight $30
May-07-19Initiated H.C. Wainwright Buy $28
Aug-28-18Initiated H.C. Wainwright Buy $28
Mar-09-18Reiterated Maxim Group Buy $20 → $15
Aug-08-17Reiterated JP Morgan Overweight $32 → $25
Jun-13-17Reiterated Maxim Group Buy $44 → $40
May-05-17Initiated BMO Capital Markets Outperform $54
Oct-19-16Initiated Robert W. Baird Outperform $40
Sep-07-16Initiated Maxim Group Buy $43
Jul-27-16Initiated Citigroup Buy $36
Jan-20-16Initiated Credit Suisse Outperform
Feb-27-21 06:15AM  
Feb-25-21 08:45AM  
12:01AM  
Feb-24-21 04:01PM  
02:30PM  
Feb-18-21 08:30AM  
Feb-17-21 07:30AM  
Feb-16-21 08:00AM  
Feb-14-21 01:32PM  
Feb-06-21 02:24AM  
Feb-02-21 08:30AM  
Feb-01-21 07:53AM  
05:30AM  
Jan-22-21 04:01PM  
Jan-07-21 04:01PM  
Jan-05-21 04:01PM  
Dec-21-20 04:02PM  
09:54AM  
Nov-20-20 04:01PM  
Nov-09-20 09:30AM  
Nov-07-20 08:22AM  
Nov-06-20 03:30PM  
Nov-05-20 05:35PM  
04:02PM  
02:45PM  
Oct-29-20 12:40PM  
12:34PM  
Oct-26-20 12:10PM  
12:00PM  
11:40AM  
09:51AM  
Oct-22-20 04:15PM  
Oct-16-20 09:30AM  
Oct-05-20 09:44AM  
Sep-28-20 05:23PM  
Sep-18-20 11:02AM  
Sep-13-20 10:10AM  
Aug-21-20 09:30AM  
Aug-11-20 03:45PM  
Aug-06-20 08:10PM  
04:02PM  
Aug-03-20 04:48PM  
Jul-30-20 12:33PM  
Jul-17-20 09:30AM  
Jul-16-20 09:30AM  
Jul-14-20 03:49PM  
Jul-09-20 08:56PM  
Jun-19-20 09:30AM  
Jun-15-20 04:05PM  
Jun-12-20 08:31AM  
Jun-03-20 03:35AM  
May-26-20 06:16PM  
12:53PM  
May-21-20 12:47PM  
May-13-20 07:08PM  
May-10-20 10:47PM  
08:59AM  
May-08-20 05:30PM  
01:05PM  
May-07-20 04:08PM  
May-04-20 09:30AM  
Apr-30-20 12:34PM  
Apr-22-20 09:30AM  
Apr-21-20 05:39PM  
Apr-16-20 07:27AM  
Apr-15-20 12:05AM  
Apr-14-20 07:52AM  
Apr-13-20 09:23AM  
Apr-08-20 10:49AM  
Apr-07-20 06:59AM  
Mar-26-20 08:34AM  
Mar-20-20 09:30AM  
Mar-14-20 02:43AM  
Mar-09-20 05:01AM  
Mar-05-20 04:09PM  
07:00AM  
Feb-29-20 08:54AM  
Feb-27-20 04:01PM  
Feb-26-20 09:30AM  
Feb-24-20 09:43AM  
Feb-20-20 11:19AM  
Feb-11-20 11:30AM  
Feb-07-20 12:00PM  
Feb-06-20 09:34AM  
Jan-23-20 11:30AM  
Jan-17-20 08:16AM  
Jan-13-20 08:30AM  
Jan-08-20 08:53AM  
Jan-07-20 11:30AM  
09:59AM  
Jan-03-20 09:55AM  
09:30AM  
09:01AM  
Dec-30-19 09:44AM  
Dec-19-19 11:30AM  
Dec-16-19 09:34AM  
Dec-07-19 12:25PM  
Dec-03-19 08:51AM  
Nov-26-19 11:27AM  
Nov-19-19 09:36AM  
Coherus BioSciences, Inc., a biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; Selexis SA; collaboration with Junshi Biosciences; and collaboration with Shanghai Junshi Biosciences, Co., Ltd for the development and commercialization of Toripalimab, Junshi Biosciences' anti-Pd-1 antibody. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anicetti Vincent RChief Operating OfficerFeb 17Option Exercise2.502,4886,22162,227Feb 19 04:11 PM
Anicetti Vincent RChief Operating OfficerFeb 17Sale17.452,48843,41859,739Feb 19 04:11 PM
Viret Jean-FredericChief Financial OfficerFeb 01Option Exercise10.057,40274,39068,697Feb 03 05:37 PM
Viret Jean-FredericChief Financial OfficerFeb 01Sale21.557,402159,51361,295Feb 03 05:37 PM
Viret Jean-FredericChief Financial OfficerJan 25Option Exercise10.0540,000402,000107,439Jan 27 04:15 PM
Viret Jean-FredericChief Financial OfficerJan 25Sale19.9546,144920,73661,295Jan 27 04:15 PM
Anicetti Vincent RChief Operating OfficerJan 19Option Exercise2.502,5006,25162,239Jan 21 04:22 PM
Anicetti Vincent RChief Operating OfficerJan 19Sale17.942,50044,85259,739Jan 21 04:22 PM
Anicetti Vincent RChief Operating OfficerDec 17Option Exercise2.502,5006,25135,069Dec 21 04:10 PM
Anicetti Vincent RChief Operating OfficerDec 17Sale17.512,50043,78032,569Dec 21 04:10 PM
Vexler VladimirChief Scientific OfficerDec 10Option Exercise2.0817,62636,72954,299Dec 11 04:39 PM
Vexler VladimirChief Scientific OfficerDec 10Sale18.0517,626318,06636,673Dec 11 04:39 PM
Vexler VladimirChief Scientific OfficerDec 09Option Exercise2.0830,00062,51486,185Dec 11 04:39 PM
Vexler VladimirChief Scientific OfficerDec 09Sale18.2449,512903,08436,673Dec 11 04:39 PM
Anicetti Vincent RChief Operating OfficerDec 07Option Exercise12.598,791110,65641,360Dec 09 05:53 PM
Anicetti Vincent RChief Operating OfficerDec 07Sale18.428,791161,89632,569Dec 09 05:53 PM
Anicetti Vincent RChief Operating OfficerDec 04Option Exercise15.3749,000753,07981,569Dec 07 04:51 PM
Anicetti Vincent RChief Operating OfficerDec 04Sale18.8549,000923,69432,569Dec 07 04:51 PM
Anicetti Vincent RChief Operating OfficerDec 03Option Exercise17.3249,756861,60282,325Dec 07 04:51 PM
Anicetti Vincent RChief Operating OfficerDec 03Sale18.6749,756929,07932,569Dec 07 04:51 PM
Anicetti Vincent RChief Operating OfficerNov 18Option Exercise12.704,28354,39436,852Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerNov 18Sale18.004,28377,09432,569Nov 19 04:16 PM
Viret Jean-FredericChief Financial OfficerNov 17Option Exercise13.501,50020,25040,269Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerNov 17Option Exercise2.502,5006,25151,056Nov 19 04:16 PM
Viret Jean-FredericChief Financial OfficerNov 17Sale17.491,99534,89638,769Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerNov 17Sale17.6618,487326,41632,569Nov 19 04:16 PM
Anicetti Vincent RChief Operating OfficerOct 19Option Exercise4.773,21715,35751,773Oct 21 04:04 PM
Anicetti Vincent RChief Operating OfficerOct 19Sale17.893,21757,55648,556Oct 21 04:04 PM
Viret Jean-FredericChief Financial OfficerOct 14Sale19.006,144116,73640,423Oct 16 04:19 PM
Anicetti Vincent RChief Operating OfficerSep 17Option Exercise7.605,00038,00153,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerSep 17Sale18.845,00094,21648,556Sep 21 05:06 PM
Anicetti Vincent RChief Operating OfficerAug 17Option Exercise7.605,00038,00153,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerAug 17Sale19.375,00096,85148,556Aug 19 04:23 PM
Anicetti Vincent RChief Operating OfficerJul 17Option Exercise11.0015,000165,00163,556Jul 21 05:04 PM
Anicetti Vincent RChief Operating OfficerJul 17Sale18.2515,000273,68748,556Jul 21 05:04 PM
Lanfear Dennis MPresident & CEOJul 01Option Exercise0.0129,994249193,258Jul 06 05:58 PM
Szela Mary TDirectorJun 22Option Exercise8.8454,997485,90054,997Jun 24 04:55 PM
Szela Mary TDirectorJun 22Sale17.5854,997966,7590Jun 24 04:55 PM
Anicetti Vincent RChief Operating OfficerJun 17Option Exercise2.502,5006,25151,056Jun 19 04:35 PM
Anicetti Vincent RChief Operating OfficerJun 17Sale17.222,50043,05048,556Jun 19 04:35 PM
Wahlstrom MatsDirectorJun 17Sale17.15200,0003,430,0200Jun 19 04:33 PM
Viret Jean-FredericChief Financial OfficerMay 20Sale17.661,27822,56946,567May 22 04:30 PM
Anicetti Vincent RChief Operating OfficerMay 18Option Exercise2.502,5006,25151,056May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerMay 18Sale17.173,09353,10748,556May 20 05:01 PM
Anicetti Vincent RChief Operating OfficerApr 20Sale17.005,15087,55047,846Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Option Exercise2.505,00012,50357,996Apr 21 04:24 PM
Anicetti Vincent RChief Operating OfficerApr 17Sale15.575,00077,85052,996Apr 21 04:24 PM
Wahlstrom MatsDirectorMar 03Sale20.12118,0662,375,409200,000Mar 05 04:31 PM